- Home
- FEBO vs ALZN Comparison
FEBO vs ALZN Comparison
Compare FEBO & ALZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FEBO
- ALZN
- Stock Information
- Founded
- FEBO 1993
- ALZN 2016
- Country
- FEBO Hong Kong
- ALZN United States
- Employees
- FEBO N/A
- ALZN N/A
- Industry
- FEBO
- ALZN Medicinal Chemicals and Botanical Products
- Sector
- FEBO
- ALZN Health Care
- Exchange
- FEBO Nasdaq
- ALZN Nasdaq
- Market Cap
- FEBO 8.0M
- ALZN 7.4M
- IPO Year
- FEBO 2023
- ALZN 2021
- Fundamental
- Price
- FEBO $0.76
- ALZN $2.52
- Analyst Decision
- FEBO
- ALZN Strong Buy
- Analyst Count
- FEBO 0
- ALZN 1
- Target Price
- FEBO N/A
- ALZN $45.00
- AVG Volume (30 Days)
- FEBO 444.4K
- ALZN 64.9K
- Earning Date
- FEBO 10-24-2025
- ALZN 09-10-2025
- Dividend Yield
- FEBO N/A
- ALZN N/A
- EPS Growth
- FEBO N/A
- ALZN N/A
- EPS
- FEBO N/A
- ALZN N/A
- Revenue
- FEBO $17,110,653.00
- ALZN N/A
- Revenue This Year
- FEBO N/A
- ALZN N/A
- Revenue Next Year
- FEBO N/A
- ALZN N/A
- P/E Ratio
- FEBO N/A
- ALZN N/A
- Revenue Growth
- FEBO 11.58
- ALZN N/A
- 52 Week Low
- FEBO $0.61
- ALZN $2.06
- 52 Week High
- FEBO $7.26
- ALZN $17.73
- Technical
- Relative Strength Index (RSI)
- FEBO 48.67
- ALZN 52.31
- Support Level
- FEBO $0.75
- ALZN N/A
- Resistance Level
- FEBO $0.84
- ALZN $2.42
- Average True Range (ATR)
- FEBO 0.06
- ALZN 0.12
- MACD
- FEBO 0.02
- ALZN -0.06
- Stochastic Oscillator
- FEBO 54.77
- ALZN 95.97
About FEBO Fenbo Holdings Limited
Fenbo Holdings Ltd is a company engaged in producing premium personal care electric appliances, principally electrical hair styling products such as straighteners, curlers, trimmers, etc., and toy products to overseas markets. It manufactures and sells products such as Straightener, Mini Straightener, and Curling Iron.
About ALZN Alzamend Neuro Inc.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.